BlackRock ESG Capital Allocation Term Trust Board Gains Key Proxy Advisor Support Against Activist
ECAT sits 18% above its 52-week low of $13.36.
Summary
BlackRock ESG Capital Allocation Term Trust announced that ISS and Egan-Jones, joining Glass Lewis, recommended shareholders vote for the incumbent board nominees, rejecting the activist investor's slate.
Key Events · Corporate Governance and Compliance · ECAT
-
Proxy Advisors Endorse Incumbent Board
ISS and Egan-Jones recommended shareholders vote for BlackRock's incumbent board nominees, with ISS supporting 7 of 9 and Egan-Jones supporting all 9.
-
Activist Slate Rejected
All three major proxy advisory firms (ISS, Egan-Jones, Glass Lewis) rejected the full slate of nominees proposed by activist investor Saba Capital Management.
-
Shareholder Meeting Nears
The annual meeting is scheduled for June 9, 2026, where shareholders will vote on board nominees.
-
Performance Highlights Cited
The filing cited improved total shareholder return, narrowed NAV discount, increased distribution rates, and share repurchase programs as reasons for supporting the current board.
Analysis · ECAT · Unknown
This filing significantly strengthens the incumbent board's position in the ongoing proxy battle with Saba Capital Management. The combined recommendations from ISS, Egan-Jones, and Glass Lewis against the activist's nominees provide a strong endorsement for the current management, making it more likely they will win the upcoming shareholder vote on June 9th.
At the time of this filing, ECAT was trading at $15.79 on NYSE in the Unknown sector. The 52-week trading range was $13.36 to $17.14. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.